UNSPSC 51284030: Doxycycline monohydrate

This classification denotes a tetracycline antibiotic with the molecular structure C22H24N2O8.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, N12000U13O chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.6.alpha.,12a.alpha.))-, monohydrate, but more commonly known as doxycycline, which bears US NIH Compound Identifier 5281011.

UNSPSC 51284030 Doxycycline monohydrate is a Commodity code that represents a single pharmaceutical product—an antibiotic in tablet or capsule form—yet the recent state and local opportunities tagged under this code show minimal direct procurement of doxycycline itself and instead reflect broader pharmaceutical purchasing programs. The code appears in solicitations for generic multi-source pharmaceutical contracts, pharmacy benefit program initiatives, medical and first aid supply bundles, and opioid-response products; only the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP explicitly names generic pharmaceuticals with specific National Drug Codes as line items, though doxycycline is not identified by name in the available summaries. State and local buyers using this code range from health agencies and cooperative purchasing consortia to municipal fire departments and county health departments, with purchasing driven by population health needs, emergency response capability, and cost containment through bulk or direct-to-manufacturer contracting.

Geographic activity centers on Minnesota (through MMCAP, which serves multiple states including Oregon), Texas (Texas Health and Human Services Commission RFI on direct-to-manufacturer pharmacy programs), and Florida (Seminole County procurement for naloxone and drug deactivation systems). Representative recent opportunities include the Minnesota Multistate Cooperative Purchasing Alliance RFP (S1070000015802) issued January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be supplied through authorized wholesalers with awards effective July 1, 2026; the Texas Health and Human Services Commission RFI (HHS0017013) posted April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs; and the City of Tampa IFB (26P00145) for medical and first aid supplies, due March 13, 2026, with an estimated contract value of $700,000 and a sheltered market set-aside for Small Local Business Enterprises. The code shows sparse direct demand for doxycycline monohydrate as a standalone product line; buyers appear to purchase it primarily as one component within bundled pharmaceutical or medical supply contracts rather than through commodity-specific solicitations.